Tag Archives: neurological disorders

February, 2017

  • 28 February

    FDA Grants Priority Review to Teva’s Tardive Dyskinesia Drug

    JERUSALEM–(BUSINESS WIRE)–Teva Pharmaceutical Industries Ltd. (NYSE and TASE:TEVA) today announced the U.S. Food and Drug Administration (FDA) has accepted the New Drug Application (NDA) and granted Priority Review for SD-809 (deutetrabenazine) for the treatment of tardive dyskinesia (TD). The FDA has assigned a Prescription Drug User Fee Act (PDUFA) goal …

April, 2016

  • 8 April

    Allergan Inks $3.3 Billion Neurological Drug Deal with Heptares

    DUBLIN and LONDON, April 6, 2016 /PRNewswire/ — Allergan plc (NYSE: AGN), a leading global pharmaceutical company, and Heptares Therapeutics, the wholly-owned subsidiary of Sosei Group Corporation (“Sosei”; TSE Mothers Index: 4565), today announced that Allergan’s wholly-owned subsidiary, Allergan Pharmaceuticals International Limited and Heptares have entered into a definitive agreement …